You are here

Amarin

Amarin axes 120 of its 385 employees, hires new CEO Patrick Holt

Amarin axes 120 of its 385 employees, hires new CEO Patrick Holt

Fierce Pharma

Flag link:

Amarin’s feud with Sarissa Capital leads to CEO Karum Mikhail’s abrupt departure

Amarin’s feud with Sarissa Capital leads to CEO Karum Mikhail’s abrupt departure

Medical Devices and Diagnostics Industry

Flag link:

Alex Denner's firm takes over Amarin, ousts non-Sarissa board members

Alex Denner's firm takes over Amarin, ousts non-Sarissa board members

Endpoints

Sarissa Capital

Flag link:

Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome

Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome

Yahoo/Benzinga

acute coronary syndrome

clinical trials

Flag link:

In antitrust suit, Hikma says Amarin locked up exclusive supply deals to shut out Vascepa generics

In antitrust suit, Hikma says Amarin locked up exclusive supply deals to shut out Vascepa generics

Fierce Pharma

Flag link:

Struggling Amarin jousts with activist investor Sarissa as board vote nears

Struggling Amarin jousts with activist investor Sarissa as board vote nears

Fierce Pharma

Flag link:

Why Amarin Stock Tumbled This Week

Why Amarin Stock Tumbled This Week

Motley Fool

Flag link:

Why Amarin Stock Was a Winner Today

Why Amarin Stock Was a Winner Today

Motley Fool

Flag link:

Amarin stands behind Vascepa after new analysis raises questions about its efficacy

Amarin stands behind Vascepa after new analysis raises questions about its efficacy

Fierce Pharma

Flag link:

Amarin turns to job cuts as generics challenge its heart pill

Amarin turns to job cuts as generics challenge its heart pill

BioPharma Dive

Flag link:

Amarin CFO resigns amid cost-cutting measures, staff reduction of 40%

Amarin CFO resigns amid cost-cutting measures, staff reduction of 40%

Endpoints

Flag link:

Amarin, after 33% revenue decline, aims to 'stabilize' US sales and grow in Europe

Amarin, after 33% revenue decline, aims to 'stabilize' US sales and grow in Europe

Fierce Pharma

Flag link:

With sales sagging, Amarin sees progress on new Vascepa digital effort in the US

With sales sagging, Amarin sees progress on new Vascepa digital effort in the US

Fierce Pharma

digital marketing

Flag link:

End-of-Year Restructuring Means Layoffs for These Companies

End-of-Year Restructuring Means Layoffs for These Companies

BioSpace

Rigel Pharmaceuticals

Esperion Therapeutics

Acorda Therapeutics

Ziopharm Oncology

Flag link:

Faced with generic rivals, Amarin cuts 400-plus sales reps as part of revamped Vascepa strategy

Faced with generic rivals, Amarin cuts 400-plus sales reps as part of revamped Vascepa strategy

Fierce Pharma

Flag link:

ESC: Amarin touts Vascepa's ability to reduce repeat heart problems as it fights generic with 'skinny label' claim

ESC: Amarin touts Vascepa's ability to reduce repeat heart problems as it fights generic with 'skinny label' claim

Fierce Pharma

Flag link:

Amarin's Vascepa patent defense ends in a loss at the Supreme Court

Amarin's Vascepa patent defense ends in a loss at the Supreme Court

Fierce Pharma

Flag link:

Amarin CEO Thero to Retire as Company Pivots Focus to Global Markets

Amarin CEO Thero to Retire as Company Pivots Focus to Global Markets

BioSpace

Flag link:

Amarin launches Vascepa in all-important Europe as it slowly bleeds share to U.S. generic

Amarin launches Vascepa in all-important Europe as it slowly bleeds share to U.S. generic

Fierce Pharma

Flag link:

Amarin vs. the Generics: Who Will Win?

Amarin vs. the Generics: Who Will Win?

Motley Fool

Flag link:

Pages